Optimal CAB Case Study: Pediatric Dolutegravir
This case study, developed by the Optimal CAB in Malawi with support from CHAI, outlines the efforts undertaken by Malawi CAB members to...
top of page
A framework to support new product introduction in national health systems
Resource Library
- May 16
CAB Case Studies from Ethiopia
These Community Advisory Board (CAB) case studies capture highlights of what CAB members considered to be some of the most impactful...
34
- Feb 27
Community Statements on DRV/r Use in 2L
In December 2022, 40+ community groups and an additional 45+ individuals released a community position statement calling on the global...
36
- Feb 16
CAB Case Studies from Tanzania
These FASTER and AIDS Free Community Advisory Board (CAB) case studies capture pediatric and adolescent activities to highlight what CAB...
26
- Feb 16
CAB Case Studies from Zambia
These FASTER and AIDS Free Community Advisory Board (CAB) case studies capture pediatric and adolescent activities to highlight what CAB...
19
- Feb 16
CAB Case Studies from Nigeria
These FASTER and AIDS Free Community Advisory Board (CAB) case studies capture pediatric and adolescent activities to highlight what CAB...
30
- Feb 16
CAB Case Studies from Uganda
These FASTER and AIDS Free Community Advisory Board (CAB) case studies capture pediatric and adolescent activities to highlight what CAB...
26
- Oct 18, 2022
Prevention Product Preference Brief
New products, including long-acting formulations, will be critical to achieve HIV treatment and prevention targets and close gaps among...
32
- Oct 18, 2022
CAB-LA Community Meeting Overview
A Community Forum: Supporting Affordable Access to Long-Acting Injectable Cabotegravir (CAB-LA) took place in Kampala, Uganda from June...
47
- Sep 12, 2022
AHD Community Advocacy Video
This video was developed by Community Advisory Board (CAB) members, and is intended to increase awareness and utilization of services for...
92
- Sep 12, 2022
Pediatric DTG Advocacy Video for Communities (English and French)
This advocacy video provides a brief overview of pDTG to encourage demand generation for the product. The video is available at the...
182
- Jul 31, 2022
Optimal CAB Case Study: Enabling and Ensuring Equitable HIV Treatment for Women
This case study, developed by the Optimal CAB with support from CHAI, outlines the mobilization of community members in response to the...
5
- Jul 31, 2022
Case Study: Community-Developed HIV Care and Treatment Literacy Improves Uptake of Optimal Medicines
This case study, developed by the Optimal CAB with support from CHAI, outlines the tremendous work done by community members developing...
6
- Jun 16, 2022
AHD Social Media Campaign
These resources, developed by Community Advisory Board (CAB) members, are intended to increase awareness and utilization of services for...
165
- Oct 18, 2021
The Community's Corner: Optimal CAB Newsletter
This newsletter shares learnings and highlights of the CHAI-Unitaid Optimal Community Advisory Board (CAB) and its members. The...
18
- Jul 9, 2021
Community Resources for Pediatric DTG Scale-Up
Optimal and FASTER CAB members, with technical support from CHAI, developed a multi-media package of treatment literacy and advocacy...
42
- Aug 1, 2020
AfroCAB / CHAI Community Consultation and Webinar Series
In response to the growing uncertainty and challenges as a result of the COVID-19 pandemic, AfroCAB and CHAI introduced the AfroCAB/CHAI...
19
- Mar 1, 2020
Communique of the Kigali Community Meeting on Dolutegravir and Weight Gain
In this meeting of people living with HIV, participants deliberated on the emerging data on DTG-associated weight gain and hyperglycemia....
8
- Dec 1, 2018
Case Study: Partnering with Communities of PLHIV Accelerates Access to Optimal Treatment
This case study outlines the process of creating the Optimal ARV Community Advisory Board (CAB) and the impact the CAB has had on...
18
- Nov 1, 2017
Optimal ARV Community Advisory Board Terms of Reference
Developed by CHAI and Unitaid, these terms of reference outline the role, responsibilities, and governance of the Optimal ARV Community...
3
bottom of page